Expanding horizons from DKD to CKD: A cardio-kidney-metabolic approach
IMPORTANCE
In order to apply for CME credits, Omnihealth Practice will collect your professional details and participation results for the corresponding College/ CME Programmes Administrator.
PLEASE ENSURE YOUR ACCOUNT DETAILS ARE CORRECT, including full name, and registration number. Omnihealth Practice is not responsible for any failure on application due to error details provided by participant. Should you have any questions, please contact [email protected]
To receive a certificate, you must achieve a passing score as designated by the corresponding college/ CME Programmes Administrator. You may view or print the certificate from RECORD, but you cannot alter it.
All the CME accredited programmes on Omnihealth Practice Education Portal are approved for healthcare professionals in Hong Kong SAR ONLY.
CME released:
3 November 2025
Valid for credit through:
2 November 2026
CME accredited by:
3 November 2025 - 2 January 2026
Hong Kong College of Community Medicine - 1.0
The Hong Kong College of Pathologists - 1.0
Hong Kong College of Physicians - 1.0
CME accredited by:
3 November 2025 - 2 November 2026
Hong Kong Doctors Union - 1.0
Endorsed by:
Hong Kong Doctors Union
CKMSynced Forum is a professional, integrated educational platform for Hong Kong healthcare professionals to receive the latest updates on international guidelines for cardio-renal-metabolic disease and related information, such as case reports, insightful articles and lectures. The platform includes interviews with numerous key opinion leaders (KOLs) in the field, from whom local healthcare professionals can gain valuable insights.
About the programme
Professor Adeera Levin from the University of British Columbia emphasizes the urgent need for early intervention in chronic kidney disease (CKD), a condition that affects over 850 million people worldwide. She highlights that even mild cases, such as those with low albuminuria and normoalbuminuric CKD, should not be overlooked. This is because CKD is a silent and progressive condition that can lead to irreversible damage and increases the risk of heart failure hospitalization, kidney function decline, and mortality.
Empagliflozin, an SGLT2 inhibitor, has shown significant clinical benefits across a broad range of CKD populations, including those in early stages and without diabetes. Notably, it may delay the need for kidney replacement therapy by more than 26 years. Prof. Levin also advocates for the use of risk assessment tools to facilitate early referrals and individualized management strategies, aiming to better address the growing burden of CKD and its complications.
Professor Adeera Levin
Professor of Medicine,
Head Division of Nephrology,
University of British Columbia,
Canada
Disclaimer
This is an independent editorial article, published and distributed through unrestricted educational support from the pharmaceutical community, for the purpose of continuing medical education only. The views expressed in this publication reflect the experience and/or opinion of the author(s) and are not necessarily those of editors, publisher, and sponsor(s). Because of rapid advances in medicine, independent verification of clinical diagnoses, medical suitability and dosage should be made before treatment prescription. The appearance of advertisement, if any, has no influence on editorial content or presentation and does not imply the endorsement of products by the publication, or its authors and editors.